From: Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
Characteristics
Total (n = 51)
Progression
No
10 (19.6%)
Yes
41 (80.4%)
PFS according to Kaplan-Meier (months)
Median
9.01
CI95
(4.87–11.41)
Minimum
1.1
Maximum
55.5
PFS rate
1 year
34.3%
2 years
19.2%
3 years
14.4%
4 years
7.2%